Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
PLX01107
- Development stage
- Preclinical
- Lead developer
- Panacela Labs
- Modality
- Small Molecules
- Administration
- Oral, Intravenous
01
Overview
PLX01107 is a small molecule carbazole derivative, part of a series of compounds referred to as xenomycins, developed by Panacela Labs (a subsidiary of Statera Biopharma). It is characterized by its antimicrobial and antifungal properties. Although Panacela Labs is primarily known for its adenovirus-based immunotherapy Mobilan, PLX01107 was identified in research abstracts as a potential anti-infective agent. The specific molecular mechanism of action remains undisclosed in available literature, and the compound appears to be in the early research or preclinical stage rather than an active clinical pipeline candidate.
- Other names
- xenomycinxenomycins
Beyond the preview
Go deeper on PLX01107.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on PLX01107.